MedTrace Logo

The Impact of Oligo-Fucoidan in Cancer Cachexia and Sarcopenia

NCT05623852 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2022-11-21

No results posted yet for this study

Summary

Fucoidan also ameliorates tumour and chemotherapy-induced muscle atrophy and -related cachectic symptoms in vivo and in vitro. To evaluate the effect of fucoidan in cancer cachexia or sarcopenia in cancer patients.

Conditions

  • Cachexia

Interventions

DIETARY_SUPPLEMENT

fucoidan

It is recommended to consume on an empty stomach, 2 servings per day, a total of 8 tablets, which can be eaten at one time or in divided doses. If it is difficult to swallow, the powder in the capsule can also be taken out and mixed with food or liquid food.

Sponsors & Collaborators

  • Asia University

    collaborator OTHER

  • Taipei Medical University WanFang Hospital

    lead OTHER

Principal Investigators

  • Szu-Yuan Wu · Asia University, Taiwan

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
20 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-01-30
Primary Completion
2024-04-30
Completion
2025-04-30

Countries

  • Taiwan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05623852 on ClinicalTrials.gov